Recommendations for benefit-risk assessment methodologies and visual representations

Pharmacoepidemiology and Drug Safety

Volumn 25, Issue 3, 2016, Pages 251-262

  Hughes, Diana ^a   Waddingham, Ed ^b   Mt Isa, Shahrul ^b   Goginsky, Alesia ^a   Chan, Edmond ^c   Downey, Gerald F ^d   Hallgreen, Christine E ^b,e   Hockley, Kimberley S ^b   Juhaeri, Juhaeri ^f   Lieftucht, Alfons ^g   Metcalf, Marilyn A ^h   Noel, Rebecca A ⁱ   Phillips, Lawrence D ^j   Ashby, Deborah ^b   Micaleff, Alain ^k  

^a PFIZER INC   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c JOHNSON AND JOHNSON   (United States)

^d AMGEN LTD   (United Kingdom)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f SANOFI   (France)

^g GLAXOSMITHKLINE   (United Kingdom)

^h GLAXOSMITHKLINE   (United States)

ⁱ ELI LILLY AND COMPANY   (United States)

^j UNIVERSITY OF LONDON   (United Kingdom)

^k MERCK SERONO S A   (Switzerland)

more..

Author keywords

Benefit risk; Decision making; Drug development; Pharmacoepidemiology; Regulation

Indexed keywords

ARTICLE; BENEFIT RISK ASSESSMENT; CASE STUDY; CLINICAL PATHWAY; MEDICAL DECISION MAKING; METHODOLOGY; PLANNING; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY ADJUSTED LIFE YEAR; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; DECISION MAKING; DRUG DEVELOPMENT; DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GOVERNMENT REGULATION; INFORMATION PROCESSING; LEGISLATION AND JURISPRUDENCE; PHARMACOEPIDEMIOLOGY; PROCEDURES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATA DISPLAY; DECISION MAKING; DRUG DISCOVERY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GOVERNMENT REGULATION; PHARMACOEPIDEMIOLOGY; RISK ASSESSMENT;

EID: 84959456351     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3958     Document Type: Article

References (49)

1. CIOMS Working Group IV. Benefit-risk balance for marketed drugs: evaluating safety signals. http://www.cioms.ch/publications/g4-benefit-risk.pdf: CIOMS. [12 January 2016]
2. European Medicines Agency. Benefit-risk methodology project. http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000314.jsp&mid=WC0b01ac0580223ed6; 2009. [12 January 2016]
3. Benefit-risk methodology project: update on work package 5: effects table pilot (phase I). (EMA/74168/2014); 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2014/02/WC500162036.pdf. [12 January 2016]
4. Structured approach to benefit-risk assessment in drug regulatory decision-making. Draft PDUFA V Implementation Plan; 2013. Available from: http://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm329758.pdf. [12 January 2016]
5. Annex 1 - Grant Agreement N° 115004. PROTECT - Description of work; 2013. Available from: https://eroombayer.de/eRoom/PH-GDC-PI-SID/IMI-PROTECT/0_10a702. [27 August 2014]
6. Mt-Isa S, Hallgreen CE, Wang N, et al. Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. Pharmacoepidemiol Drug Saf 2014; 23(7): 667-78.
7. Hunink M, Glasziou P, Siegel J, et al. Decision Making in Health and Medicine: Integrating Evidence and Values. Cambridge University Press: Cambridge, 2001.
8. Hammond JS, Keeney RL, Raiffa H. Smart Choices: A Practical Guide to Making Better Decisions. Harvard Business School Press: Boston, MA, 2002.
9. Coplan PM, Noel RA, Levitan BS, Ferguson J, Mussen F. Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines. Clin Pharmacol Ther 2011 02; 89(2): 312-5.
10. Levitan BS, Andrews EB, Gilsenan A, et al. Application of the BRAT framework to case studies: observations and insights. Clin Pharmacol Ther 2011; 89(2): 217-24.
11. Mussen F, Salek S, Walker S. Benefit-risk Appraisal of Medicines. John Wiley & Sons, Ltd: Oxford, 2009.
12. Dodgson J, Spackman M, Pearman A, Phillips LD. Multi-criteria analysis: a manual. 2000.
13. Keeney RL, Raiffa H. Decisions With Multiple Objectives: Preference and Value Tradeoffs. John Wiley: New York, 1976.
14. Tervonen T, Figueira JR. A survey on stochastic multicriteria acceptability analysis methods. J Multi-Criteria Decis Anal 2008; 15(1-2): 1-14.
15. Tervonen T, van Valkenhoef G, Buskens E, Hillege HL, Postmus D. A stochastic multicriteria model for evidence-based decision making in drug benefit-risk analysis. Statist Med 2011; 30(12): 1419-28.
16. Lahdelma R, Hokkanen J, Salminen P. SMAA - stochastic multiobjective acceptability analysis. Eur J Oper Res 1998; 106(1): 137-43.
17. Holden WL, Juhaeri J, Dai W. Benefit-risk analysis: a proposal using quantitative methods. Pharmacoepidemiol Drug Saf 2003; 12(7): 611-6.
18. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318(26): 1728-33.
19. Attia J, Page J, Heller RF, Dobson AJ. Impact numbers in health policy decisions. J Epidemiol Community Health 2002; 56(8): 600-5.
20. Heller RF, Dobson AJ, Attia J, Page J. Impact numbers: measures of risk factor impact on the whole population from case-control and cohort studies. J Epidemiol Community Health 2002; 56(8): 606-10.
21. Heller RF, Buchan I, Edwards R, Lyratzopoulos G, McElduff P, Leger SS. Communicating risks at the population level: application of population impact numbers. BMJ 2003; 327(7424): 1162-5.
22. Verma A, Torun P, Harris E, et al. Population impact analysis: a framework for assessing the population impact of a risk or intervention. J Public Health (Oxf) 2012; 34(1): 83-9.
23. Chuang-Stein C, Entsuah R, Pritchett Y. Measures for conducting comparative benefit: risk assessment. Drug Inf J 2008; 42(3): 223-33.
24. Korting H, Schafer-Korting M. The Benefit-risk Ratio. A Handbook for the Rational use of Potentially Hazardous Drugs. CRC Press LLC: Boca Raton, 1999.
25. Payne JT, Loken MK. A survey of the benefits and risks in the practice of radiology. CRC Crit Rev Clin Radiol Nucl Med 1975; 6(3): 425-39.
26. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan 2006; 21(5): 402-8.
27. Ried W. QALYs versus HYEs-what's right and what's wrong. A review of the controversy. J Health Econ 1998; 17(5): 607-25.
28. Gelber RD, Cole BF, Gelber S, Aron G. Comparing treatments using quality-adjusted survival: the Q-twist method. Am Statistician 1995; 49(2): 161-9.
29. Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 1989; 7(1): 36-44.
30. Garrison LP, Towse A, Bresnahan BW. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Aff (Millwood ) 2007; 26(3): 684-95.
31. Lynd LD, Najafzadeh M, Colley L, et al. Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making-a case study of alosetron in irritable bowel syndrome. Value Health 2010; 13(4): 411-7.
32. Minelli C, Abrams KR, Sutton AJ, Cooper NJ. Benefits and harms associated with hormone replacement therapy: clinical decision analysis. BMJ 2004; 328(7436): 371.
33. Lynd LD, O'Brien BJ. Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis. J Clin Epidemiol 2004; 57(8): 795-803.
34. van Staa TP, Smeeth L, Persson I, Parkinson J, Leufkens HG. What is the harm-benefit ratio of cox-2 inhibitors? Int J Epidemiol 2008; 37(2): 405-13.
35. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002; 21(16): 2313-24.
36. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23(20): 3105-24.
37. Nixon RM, Bansback N, Brennan A. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat Med 2007; 26(6): 1237-54.
38. Ryan M, Gerard K, Amaya-Amaya M. Using Discrete Choice Experiments to Value Health and Health Care. Springer: Dordrecht, The Netherlands, 2008.
39. Ryan M, Hughes J. Using conjoint analysis to assess women's preferences for miscarriage management. Health Econ 1997; 6(3): 261-73.
40. Ryan M, Bate A, Eastmond CJ, Ludbrook A. Use of discrete choice experiments to elicit preferences. Qual Health Care 2001; 10: I55-60.
41. Recommendations for the methodology and visualisation techniques to be used in the assessment of benefit and risk of medicines; 2013. Available from: http://www.imi-protect.eu/documents/HughesetalRecommendationsforthemethodologyandvisualisationtechniquestobeusedintheassessmento.pdf. [12 January 2016]
42. Sutton AJ, Cooper NJ, Abrams KR, Lambert PC, Jones DR. A bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty. J Clin Epidemiol 2005; 58(1): 26-40.
43. Sarac SB, Fau RC, Fau RM, et al. A comprehensive approach to benefit-risk assessment in drug development. Basic Clinical Pharmacol Toxicol JID 101208422 1018.
44. Phillips LD. Benefit-risk modeling of medicinal products: methods and applications. In Benefit-risk assessment in pharmaceutical research and development, Sashegyi A, Felli J, Noel R (eds.). CRC Press: Boca Raton, FL, 2013.
45. Review of visualisation methods for the representation of benefit-risk assessment of medication: Stage 2 of 2 [Internet]; c2013. Available from: http://www.imi-protect.eu/documents/ShahruletalReviewofvisualisationmethodsfortherepresentationofBRassessmentofmedicationStage2A.pdf. [27 August 2014]
46. Hallgreen C, Mt-Isa S, Lieftucht A, et al. Literature review of visual representation of the results of benefit-risk assessments of medicinal products. Pharmacoepidemiol Drug Saf 2016; 25(3): 238-250.
47. ICH. Final concept paper, 15 December 2010: periodic safety update reports for marketed drugs E2C(R2) and gap and potential improvement analysis of ICH E2C, E2E and E2F. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2C/Concept_papers/E2C_R2__Final_Concept_Paper_December_2010.pdf: ICH; 2010. [12 January 2016]
48. Franson T, Bonforte P. Benefit-risk in the US regulatory context. In Benefit-risk assessment in pharmaceutical research and development, Sashegyi A, Felli J, Noel R (eds.). CRC Press: Boca Raton, FL, 2013.
49. IMI ADVANCE; 2014. Available from: http://www.advance-vaccines.eu/. [12 January 2016]